Study Summary
Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of combination therapies with adagrasib in patients with advanced NSCLC with TPS ≥ 1% and KRAS G12C mutation
- Advanced Non Small Cell Lung Cancer (NSCLC)
- Metastatic Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: 30 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Cohort B: PD-L1 TPS≥ 1%
1 of 2
Cohort A: PD-L1 TPS≥ 1%
1 of 2
Experimental Treatment
90 Total Participants · 2 Treatment Groups
Primary Treatment: Cohort B: PD-L1 TPS≥ 1% · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 25th, 2021
Last Reviewed: November 28th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.